trending Market Intelligence /marketintelligence/en/news-insights/trending/qWUkhQmdeGCvNr70c5ygCw2 content
Log in to other products

Login to Market Intelligence Platform

 /


Looking for more?

Contact Us

Request a Demo

You're one step closer to unlocking our suite of comprehensive and robust tools.

Fill out the form so we can connect you to the right person.

If your company has a current subscription with S&P Global Market Intelligence, you can register as a new user for access to the platform(s) covered by your license at Market Intelligence platform or S&P Capital IQ.

  • First Name*
  • Last Name*
  • Business Email *
  • Phone *
  • Company Name *
  • City *
  • We generated a verification code for you

  • Enter verification Code here*

* Required

In This List

Delcath Systems updates reverse stock split ratio to 1-for-700

Gauging Supply Chain Risk In Volatile Times

S&P Global Market Intelligence

Cannabis: Hashing Out a Budding Industry

Segment

IFRS 9 Impairment How It Impacts Your Corporation And How We Can Help

The Market Intelligence Platform


Delcath Systems updates reverse stock split ratio to 1-for-700

Delcath Systems Inc. has increased the size of its reverse stock split to a ratio of 1-for-700.

The split will cut the New York-based company's estimated 1.4 billion issued and outstanding shares of common stock down to approximately 2.1 million. The move will take effect Dec. 24 and is larger than the company's previous ratio of 1-for-100.

American Stock Transfer & Trust Co. LLC is acting as the exchange agent and transfer agent for the reverse stock split.

Delcath Systems treats primary and metastatic liver cancers. Its investigational products include melphalan hydrochloride for injection, which is used to administer high-dose chemotherapy to the liver.